Human Papillomavirus and the HPV Vaccine: Are the Benefits Worth the Risks?

Nursing Clinics of North America

Volumn 44, Issue 3, 2009, Pages 293-299

  Knudtson, Mary ^a   Tiso, Susan ^a   Phillips, Susanne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gardasil vaccine; Human papillomavirus; Sexually transmitted infections

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; CHILD; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; FEMALE; HUMAN; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; NURSE ATTITUDE; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SAFETY; UNITED STATES; UTERINE CERVIX TUMOR; VACCINATION; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; CHILD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; NURSE'S ROLE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS; SAFETY; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 68349117365     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnur.2009.06.005     Document Type: Review

References (22)

1. Weinstock H., Berman S., and Cates Jr. W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 36 1 (2004) 6-10
2. Dempsey A.F., and Koutsky L.A. National burden of genital warts: a first step in defining the problem. Sex Transm Dis 35 4 (2008) 361-362
3. Dunne E.F., Nielson C.M., Stone K.M., et al. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 194 8 (2006) 1044-1057
4. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 297 8 (2007) 813-819
5. Weller Susan C., Stanberry, and Lawrence R. Estimating the population prevalence of HPV. JAMA 297 8 (2007) 876-878
6. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 25 (2006) 2645-2654
7. Bosch F.X., and de Sanjose S. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
8. Winer R.L., Lee S., Hughes J.P., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 3 (2003) 218-226
9. Moscicki A., Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285 23 (2001) 2995-3002
10. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 7 (1998) 423-428
11. In: Roush S., MCIntyre L., and Baldy L. (Eds). Manual for the surveillance of vaccine-preventable diseases (2008), Centers for Disease Control and Prevention, Atlanta (GA) No. 4
12. National Institute of Health. Cervical cancer. NIH Consensus Statement 14 1 (1996) 1-38
13. Palefsky J.M., and Holly E.A. Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 31 (2003) 41-46
14. Castellsague X., and Munoz N. Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 31 (2003) 20-28
15. Lowy D.R., and Frazer I.H. Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 31 (2003) 111-116
16. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 9574 (2007) 1693-1702
17. Joura E.A., Kjaer S.K., Wheeler C.M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26 5 (2008) 6844-6851
18. Center for Disease Control and Prevention. Human papillomavirus: HPV information for clinicans 2007. Available at: http://www.cdc.gov/std/HPV/STDFact-HPV-vaccine-hcp.htm.
19. Balog J.E. The moral justification for a compulsory human papillomavirus vaccination program. Am J Public Health 99 4 (2009) 616-622
20. Datta S.D., Koutsky L.A., Ratelle S., et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 148 7 (2008) 493-500
21. Singh G., Miller B., and Hankkey B. Persistent area socioeconomic disparities in US incidence of cervical cancer, mortality, state and survival. Cancer 101 (2004) 1051-1057
22. Adams M., Jasani B., and Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 25 16 (2007) 3007-3013